All Notebooks | Help | Support | About
Archives
Authors
Sections
Tools
Show/Hide Keys
12th November 2017 @ 06:11
Attached Files
10th November 2017 @ 09:45

Malaria is a majority of dangerous disease in some poor area,  which will kill a lot of people. Also, there are most of drug which has drug resistance. Hence, Open Source Malaria was created in that moment. This experiment is included in the project of Open Source Malaria. This experiment uses 2,6-dichloropyrazine as the start material. During the whole produces, the experiment used the Thin layer chromatography(TLC), which uses molecular polar to separate mixture and check the reaction to be reacted and Nuclear Magnetic Resonance spectroscopy (NMR), which can identify the different chemical environmental hydro to make sure about the purify product. Both of them are useful technologies, to analysis and check whether the each step’s product is purification. Otherwise, there is some errors in experiment. Finally, the experiment could not do the last step to synthesis the target because some compound or some chemical environment which can not allow the reaction to be done. The experiment is unsuccessful.  

 

REPORT

report.docx

 

POSTER

poster yang.pptx
Attached Files
21st August 2017 @ 06:52

summary

this step is order to synthesis 5-chloro-3-(4-chlorophenyl)[1,2,4]triazolo[4,3-a]pyrazine to analysis the possible to form the target product

3.png

 

reference

 I just write the procedure to refer to the reference ( in the blow) and I am confused about the extraction agent is suitable for my product. Therefore, I highlight about the latter part.

 

https://au mynotebook.labarchives.com/doc/view/NjMuN3wyNTQyNC80OS9FbnRyeVBhcnQvNzI4NTI1MjA2fDE2MS4 nb_id=MzMwNTEuMjAwMDAwMDAwMDA0fDI1NDI0LzI1NDI0L05vdGVib29rLzg5MjQwOTYxNHw4Mzg5OS4y&page_num=0

procedure

Compound

Amount

(mg or mL)

n (mmol)

eq.

MW

density

 (if liquid)

(E)-2-Chloro-(2-(4-chloro)-benzylidene)hydrazineyl)prazine

0.6g

2.26mmol

1

265.13g/mol

 

(Diacetoxyiodo)benzene_____(PIDA)

0.79g

2.46mmol

1.09

322.096g/mol

 

DCM(CH2Cl2)

20ml

 

 

84.93g/mol

 

saturated solution

25ml

 

 

84.007 g/mol

 

 

 

 

 

 

 

5-chloro-3-(4-chlorophenyl)[1,2,4]triazolo[4,3-a]pyrazine

 

NONE

 

 

262.13g/mol

 


(E)-2-Chloro-(2-(4-chloro)-benzylidene)hydrazineyl)prazine (0.6 g, 2.26mmol, 1 equiv.) was dissolved in DCM (16.7 mL) and PhI(OAc)2 (0.79g, 2 mmol, 1 equiv.) was added. The solution was stirred at rt for 2 hours. The reaction was diluted with DCM (4.75 mL) and quenched using sat. NaHCO3  (12.5 mL). The aqueous layer was extracted with DCM (8.35 mL) and the combined organic layers were washed with a sat. NaHCO3 (12.5mL) and brine (8.35 mL). The organic layer was dried with MgSO4 and concentrated under reduced pressure.  Then we get the 0.173g yellow crystal. The therapoy is 29.2%


risk assesment

Risk Assesment from yang.pdf


data 

TLC

531849928049343842.jpg


the nmr analysis will be published next time



Attached Files